Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Influenza VLP Vaccine (recombinant)
Influenza VLP Vaccine · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Low dose | EXPERIMENTAL | - |
| High dose | EXPERIMENTAL | Investigational Influenza VLP Vaccine 60ug/strain |
| TIV | ACTIVE_COMPARATOR | Trivalent Influenza Vaccine 15ug/strain, Commercially Licenced |
| PBS | PLACEBO_COMPARATOR | - |
| Mid dose | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Influenza VLP Vaccine | BIOLOGICAL | Single dose; 0.5mL |
| TIV | BIOLOGICAL | Trivalent Influenza Vaccine 15ug/strain, commercially licensed |
| Placebo | BIOLOGICAL | phosphate-buffered saline (PBS) |
| Influenza VLP Vaccine (recombinant) | BIOLOGICAL | Single injection Day 0; 0.5mL |
Inclusion Criteria: 1. Healthy male or female \> 60 years of age at the time of the vaccination. 2. Informed consent must be obtained from the subject prior to beginning any study specific procedures indicating that they understand the purpose of this study and are willing to adhere to the procedur...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE3 | Quadrivalent influenza vaccine (split virion), inactivated |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
Influenza VLP Vaccine is a recombinant vaccine candidate developed for the prevention of influenza, including seasonal influenza. It is designed to stimulate an immune response against influenza virus. It is being studied in healthy adult and older adult populations, including adults aged 60 years and older.
Influenza VLP Vaccine is developed by Novavax, Inc., which trades on the Nasdaq under the ticker NVAX. Novavax is the sponsor of the clinical trials evaluating this recombinant virus-like particle vaccine candidate for seasonal influenza.
Influenza VLP Vaccine is in Phase 2 clinical development. It is an investigational vaccine candidate and has not been approved by the FDA. Two Phase 2 trials have been completed, and no trials are currently active.
Influenza VLP Vaccine has been evaluated in completed Phase 2 trials, including NCT01014806 in older adults, NCT00903552 in healthy adults, and NCT00754455 in healthy adults. All three trials were conducted in the United States and enrolled a total of 784 participants.
Yes, Influenza VLP Vaccine (recombinant) is an alternative name for Influenza VLP Vaccine. Both names refer to the same Novavax-developed recombinant virus-like particle vaccine candidate for seasonal influenza.